Search
Clinician Ordering Portal
Scientific Evidence
Incorporation of the 40-gene expression profile (40-GEP) test to improve treatment decisions in high-risk cutaneous squamous cell carcinoma (cSCC) patients: case series and algorithm
May 2023
Cutaneous squamous cell carcinoma (cSCC) has become a significant public health issue due to its rapidly rising incidence and an estimated 1.8 million newly diagnosed cases annually. As with other cancers, treatment decisions for patients with cSCC are based primarily on a patient’s risk for poor outcomes.
Publication: Clinical, Cosmetic and Investigational Dermatology
A tissue systems pathology test enables risk-aligned management of patients with non-dysplastic Barrett’s esophagus: a case series at an expert foregut surgery center
May 2023
Publication: Podium presentation (643) at DDW 2023, Chicago
A tissue systems pathology test enables standardized, risk-aligned management of patients with Barrett’s esophagus
May 2023
Publication: Poster presentation (Tu1271) at DDW 2023, Chicago
A tissue systems pathology test outperforms standard clinicopathic variables in predicting progression in patients with Barrett’s esophagus
May 2023
Publication: Podium presentation (222) at DDW 2023, Chicago
A tissue systems pathology test objectively risk-stratifies patients with Barrett's esophagus: results from a multicenter U.S. clinical experience
May 2023
Publication: Poster presentation (Tu1272) at DDW 2023, Chicago
A tissue systems pathology test has significant clinical utility to standardize management leading to improved health outcomes for Barrett’s esophagus patients with low-grade dysplasia
May 2023
Publication: Poster presentation (Tu1270) at DDW 2023, Chicago
Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies
Mar 2023
Independent multi-center study demonstrates risk-aligned treatment plans guided by DecisionDx-Melanoma lead to better patient outcomes.
Publication: Archives of Derm Research
Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: A rapid review and meta-analysis
Mar 2023
The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study
Jan 2023
DecisionDx-Melanoma test results influenced 85% of clinicians’ decisions regarding the SLNB surgical procedure. Use of the test results could help avoid unnecessary procedures in low-risk patients whose tumor biology indicates they could safely forgo the procedure.
Publication: Current Medical Research and Opinion
Incorporating prognostic gene expression profile assays into the management of cutaneous melanoma: an expert consensus panel report
Jan 2023
Expert panel of 6 key opinion leaders in dermatology consensus panel unanimously approved eleven usage guidelines and consensus supporting statements for the appropriate use of GEP testing.
Publication: SKIN: Journal of Cutaneous Melanoma
Improved prognostic guidance by the 31-gene expression profile test for clinical decisions after a negative lymph node for patients with cutaneous melanoma
Jan 2023
Using 31-GEP results to guide clinical management and surveillance based on personalized risk of MSS can direct care, improving patient outcomes.
Publication: Poster, presented at Winter Clinical Dermatolog conference- Hawaii Jan 13-18 2023
Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomized controlled trials
Jan 2023
Major depressive disorders are prevalent conditions with limited treatment response and remission. Pharmacogenomics tests including CYP2D6 and CYP2C19 genomic variants provide the most reliable actionable approach to guide choice and dosing of antidepressants in major depression to improve outcomes.
Publication: Neuroscience & Behavioral Reviews